ABAT, ADSL, ALDH5A1, ALDH7A1, ALG13, ANKRD11, ARFGEF2, ARHGEF9, ARID1B, ARX, ATP1A2, ATP6AP2, BRAT1, CACNA1A, CACNA1E, CACNB4, CASK, CASR, CDKL5, CHD2, CHRNA2, CHRNA4, CHRNB2, CLCN4, CLN3, CLN5, CLN6, CLN8, CLTC, CNTNAP2, CSTB, CTSD, CUL4B, CUX2, DCX, DDX3X, DEPDC5, DNM1, DNM1L, DOCK7, DYRK1A, EEF1A2, EHMT1, EPM2A, FGF12, FLNA, FOLR1, FOXG1, GABBR2, GABRA1, GABRB1, GABRB2, GABRB3, GABRG2, GAMT, GATM, GNAO1, GNB1, GOSR2, GRIN1, GRIN2A, GRIN2B, HCN1, HECW2, HNRNPU, IQSEC2, IRF2BPL, KANSL1, KCNA1, KCNA2, KCNAB1, KCNB1, KCNC1, KCNH1, KCNJ10, KCNQ2, KCNQ3, KCNT1, KCNT2, KCTD7, KIF5C, LGI1, LIAS, MBD5, MECP2, MEF2C, MFSD8, MOCS1, MOCS2, MTOR, NALCN, NECAP1, NEDD4L, NEXMIF, NHLRC1, NPRL2, NPRL3, NRXN1, OPHN1, PACS1, PACS2, PAFAH1B1, PCDH19, PHF6, PHGDH, PIGA, PIGN, PIGO, PIGT, PLCB1, PLPBP, PNKP, PNPO, POLG, PPP2CA, PPP3CA, PPT1, PRICKLE1, PRICKLE2, PRRT2, PURA, QARS1, RELN, RHOBTB2, ROGDI, SCARB2, SCN1A, SCN1B, SCN2A, SCN3A, SCN8A, SIK1, SLC13A5, SLC25A19, SLC25A22, SLC2A1, SLC35A2, SLC6A1, SLC9A6, SMC1A, SMS, SNAP25, SPATA5, SPTAN1, ST3GAL3, ST3GAL5, STX1B, STXBP1, SYN1, SYNGAP1, SYNJ1, SZT2, TBC1D24, TCF4, TPP1, TSC1, TSC2, TUBB2A, UBA5, UBE3A, USP9X, WDR45, WDR62, WWOX, ZEB2
Epilepsy/Seizure NGS Panel
Epilepsy/Seizure NGS Panel
The Epilepsy/Seizure NGS Panel is a 165-gene panel intended for patients with a diagnosis of epilepsy or seizures.
16q24.3 microdeletion syndrome, 5q14.3 microdeletion syndrome, Adenylosuccinate lyase deficiency, Alternating hemiplegia of childhood, Amelocerebrohypohidrotic syndrome, Amish infantile epilepsy syndrome, Autosomal dominant hypocalcemia, Benign familial neonatal and infantile seizures, Borjeson-Forssman-Lehmann syndrome, Christianson syndrome, Coffin-Siris syndrome, Cortical dysplasia-focal epilepsy syndrome, Dravet syndrome, Early infantile epileptic encephalopathy, EAST syndrome, Encephalopathy due to defective mitochondrial and peroxisomal fission, Episodic ataxia, Familial focal epilepsy with variable foci, Familial infantile convulsions with paroxysmal choreoathetosis, Familial or sporadic hemiplegic migraine, Frontometaphyseal dysplasia, GABA-transaminase deficiency, Generalized epilepsy with febrile seizures, Guanidinoacetate methyltransferase deficiency, Hyperekplexia-epilepsy syndrome, Idiopathic generalized epilepsy, Isolated focal cortical dysplasia type IIa, Juvenile myoclonic epilepsy, Kleefstra syndrome, Koolen-De Vries syndrome, L-Arginine:glycine amidinotransferase deficiency, Lafora disease, Lennox-Gastaut syndrome, Lipoic acid synthetase deficiency, Lissencephaly, Miller-Dieker syndrome, Mitochondrial recessive ataxia syndrome, Molybdenum cofactor deficiency, Mowat-Wilson syndrome, Neurodegeneration due to cerebral folate transport deficiency, Neuronal ceroid lipofuscinosis, Nocturnal frontal lobe epilepsy, Periventricular nodular heterotopia, Phosphoglycerate dehydrogenase deficiency, Pitt-Hopkins syndrome, Pontocerebellar hypoplasia, Presynaptic congenital myasthenic syndrome, Primary microcephaly, Progressive epilepsy-intellectual disability syndrome, Finnish type, Progressive myoclonic epilepsy, Pyridoxine-dependent epilepsy, Rett syndrome, Seckel syndrome, Succinic semialdehyde dehydrogenase deficiency, Susceptibility to malignant hyperthermia, Temple-Baraitser syndrome, Tuberous sclerosis, Unverricht-Lundborg disease, West syndrome, Wiedemann-Steiner syndrome, X-linked intellectual disability\, Cabezas type, X-linked intellectual disability\, Cantagrel type, X-linked intellectual disability\, Najm type
Clinical Information
Epilepsy is a common disorder with a significant portion of cases having some degree of genetic contribution. This includes multifactorial, polygenic, chromosomal, copy number variants, and single gene disorders. This panel provides a cost effective and comprehensive strategy to evaluate for single gene causes of seizure disorders. Syndromic and non-syndromic forms of epilepsy are included in this panel. Identifying the underlying etiology and genetic cause of epilepsy may influence or directly impact medical management. For example, some medications are contraindicated when particular gene variants are present.
Technical Information
This panel is performed by Next Generation Sequencing and covers the coding regions of the listed genes and the flanking intronic sequences. Promoter, 3′ untranslated sequences, and deep intronic sequences are also covered, but only known disease-causing variants in these regions will be reported. Variants identified on the panel are confirmed with Sanger sequencing if they do not meet certain quality thresholds. Large deletions and duplications (CNVs) affecting the genes of the panel can be detected; however, due to defined settings in the analysis software, CNVs smaller than 2-kb may not be identified (for example, some small exonic level copy number changes may not be identified). Please note that certain types of genetic alterations including trinucleotide repeat expansions, methylation abnormalities, and balanced rearrangements (e.g., inversions, reciprocal translocations) may not be detected by the current analysis.
Specimen Requirements
Transport Instructions
Associated Tests
- EpiSign Complete
- EpiSign Variant
- Fragile X Syndrome: FMR1 Methylation Analysis
- Neurological Enzyme Panel
- Neuronal Ceroid Lipofuscinosis 1 (CLN1): Palmitoyl-Protein Thioesterase 1 Enzyme Analysis
- Neuronal Ceroid Lipofuscinosis 2 (CLN2): Tripeptidyl Peptidase 1 Enzyme Analysis
- QUICK Analysis
- Rett Syndrome: MECP2 Deletion/Duplication MLPA
- Rett Syndrome: MECP2 Sequencing
Connect With Our Experts
Call 1-800-473-9411 to speak with our team of laboratory genetic counselors for questions or additional information.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC
